

Coverage Guidance for TMS for OCD

COVERAGE INDICATIONS, LIMITATIONS, AND/OR MEDICAL NECESSITY

Introduction: Transcranial Magnetic Stimulation (TMS) is a non-invasive treatment that uses pulsed magnetic fields to induce an electric current in a localized region of the cerebral cortex. An electromagnetic coil placed on the scalp induces focal, patterned current in the brain that temporarily modulates cerebral cortical function. Capacitor discharge provides electrical current in alternating on/off pulses. Stimulation parameters may be adjusted to alter the excitability of the targeted structures in specific cortical regions. TMS parameters include cranial location, stimulation frequency, pattern, duration, intensity and the state of the brain under the coil.

History/Regulatory: In October 2008, conventional rTMS with a figure-8 coil was FDA cleared for the treatment of adults with major depressive disorder (MDD) who had one failed medication trial. TMS has since been established as a treatment with an excellent safety profile. rTMS with the H1 coil was cleared in January of 2013 for adults with MDD who failed any number of treatments. rTMS (dTMS) with the H7 coil was cleared in August of 2018 as an adjunctive treatment for adults with Obsessive Compulsive Disorder (OCD). In its approval, The FDA noted 38% of patients receiving dTMS had at least a 30% reduction in the Yale-Brown Obsessive-Compulsive Scale (YBOCS) score, compared with 11% of patients who received sham treatment.¹ Post marketing analysis of 219 patients from 22 community sites demonstrated a response rate of 57.9% after 29 sessions, with improving response rates and response magnitudes with longer treatment durations, 50% at 31 days and 78% after 60 days.²⁵ Clinical sub analysis and electrophysiological studies suggest that the mechanism of action of dTMS for OCD is different from medications and CBT, and non-response to either is not a predictor of response to TMS.^{9,26,27} Additionally, patients with comorbid OCD and MDD generally only needed treatment with H7/OCD protocol to treat both conditions.²⁸ In August 2020, the Cool D-B80 coil was also FDA cleared for adjunct treatment of OCD.²⁴

Obsessive Compulsive Disorder (OCD): Unlike major depressive disorder (MDD), which tends to be an episodic illness, OCD is a chronic lifelong disorder that typically begins in adolescence.^{2,3} It is the fourth most common mental illness and can cause significant distress and disability. Patients exhibit obsessions, compulsions and avoidance symptoms, which are correlated to abnormal activity in the cortico-striato-thalamic-cortical circuit.⁴ Severe refractory cases are referred for neurosurgery (lesional or with an implanted brain stimulator).⁵⁻⁸ There is now a non-invasive approach using TMS to target the abnormal circuitry of OCD. In this approach, a coil is placed over the anterior cingulate cortex, which is 4 cm anterior to the foot motor cortex and beneath the dorsomedial prefrontal cortex.^{1,9} TMS for OCD is performed 5 days per week for 6 weeks for a total of 29 sessions. Prior to each treatment, patients undergo individually tailored provocations to activate the abnormal OCD circuitry (for instance, asking a person with germ-related obsessions and compulsions to touch the floor and then not use hand sanitizer). There is no need for anesthesia or analgesia and there are no activity restrictions before or after treatment (e.g., driving, working, operating heavy machinery). Other non-invasive treatments for OCD include cognitive behavioral therapy (CBT) and pharmacotherapy. CBT specific to OCD is known as exposure and response prevention (ERP), utilizing a trained cognitive behavioral therapist to guide the treatment.^{10,11} Pharmacotherapy options include serotonin reuptake inhibitors (SRIs), such as fluoxetine, paroxetine, sertraline and fluvoxamine, and the predominantly serotonergic tricyclic antidepressant clomipramine.¹²⁻¹⁷

* Approved by the CTMSS Board of Directors on February 2, 2021

INDICATIONS FOR COVERAGE

TMS for OCD will be covered if it is prescribed by a licensed psychiatrist who is trained in the use of TMS, and if the patient meets the below criteria.

Initial Treatment: TMS for OCD is considered medically necessary for use in an adult who meets #1 and #2 of the following criteria:

1. Has a confirmed diagnosis of Obsessive-Compulsive Disorder (OCD) as per DSM-5 criteria

AND

2. One or more of the following:

Resistance to treatment as evidenced by persistent OCD symptoms after two indicated therapies (two medications or one medication plus psychotherapy) were tried each for a minimum of eight weeks; CBT psychotherapy, while a treatment option, is not required as a pre-requisite to TMS OCD treatment; or

Inability to tolerate psychopharmacologic agents as evidenced by trials with two distinct psychopharmacologic agents; or

History of response to TMS for OCD in the past was clinically meaningful; or

Resistance to treatment with CBT as evidenced by persistent OCD symptoms despite 8 weeks of ERP with a CBT therapist; or

If the patient is currently receiving antipsychotics, opioids, benzodiazepines, glutamatergic agents or other agents which could be considered investigational or relatively risky treatments, TMS may be considered reasonable and necessary and a safer alternative than additional treatment trials.¹⁸⁻²⁰

The order for treatment (or retreatment) must be written by a psychiatrist (MD or DO) who has examined the patient, reviewed the record, and is prescribing an evidence-based OCD TMS protocol. This physician shall oversee the treatment, but does not have to personally administer the sessions or be in the area. The physician must be reachable and interruptible in case of problems.

COVERAGE LIMITATIONS

The benefits of TMS use must be carefully considered against the risk of potential side effects in patients with any of the following:

Seizure disorders or medical conditions may increase the risk of seizure. There is always an extremely small chance for TMS to cause a seizure during the TMS session in non-epileptics.²¹⁻²²

The seizure risk with TMS is somewhat higher in patients with known seizure risk factors, however it remains a very low risk.²³ TMS may be indicated in patients with known seizure risk factors if the potential benefit outweighs the risk.

* Approved by the CTMSS Board of Directors on February 2, 2021

Repetitive TMS is contraindicated in the presence of an implanted magnetic-sensitive medical device located less than or equal to 10 cm from the TMS coil, such as a cochlear implant. MRI safe and MRI-conditional aneurysm clips or coils, staples or stents are not a contraindication for TMS. Dental amalgam fillings are not affected by the magnetic field and are acceptable for use with TMS. Similarly, cervical fusion and fixation devices, and hypoglossal and vagal nerve stimulators, are not contraindications for TMS treatment.

UTILIZATION GUIDELINES

The treatment must be provided by a device cleared by the FDA for the purpose of TMS for OCD. It is expected that the services will be performed as indicated by current medical literature and standards of practice.

TMS for adolescents with OCD may be appropriate if there is a higher level of treatment resistance. These cases should be reviewed individually for medical necessity and considered a compassionate use.

TMS is reasonable and necessary for a minimum of 29 visits over a 6-week period. Extensions in 2 to 4-week increments will be cleared based on clinical need with evidence of response from the first 29 sessions.

If patients cannot come in five days a week, treatments may be administered three days a week over a longer period of time.

Retreatment may be considered for patients who met the guidelines for initial treatment and experienced at least a 30% reduction in the YBOCS score, as long as the improvement persisted for at least one month after the prior treatments ended.

There are currently two FDA cleared TMS devices for the treatment of OCD, however as other devices are approved, these criteria can be interpreted to apply to those devices as well.

CODING

CPT/HCPCS Codes Group 1 Paragraph:

Group 1 Codes: CODE	DESCRIPTION
90867 x 1	THERAPEUTIC REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION (TMS) TREATMENT; INITIAL, INCLUDING CORTICAL MAPPING, MOTOR THRESHOLD DETERMINATION, DELIVERY AND MANAGEMENT
90868 (all other days)	THERAPEUTIC REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION (TMS) TREATMENT; SUBSEQUENT DELIVERY AND MANAGEMENT, PER SESSION
90869 (once a week)	THERAPEUTIC REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION (TMS) TREATMENT; SUBSEQUENT MOTOR THRESHOLD RE-

* Approved by the CTMSS Board of Directors on February 2, 2021

	DETERMINATION WITH DELIVERY AND MANAGEMENT
--	--



* Approved by the CTMSS Board of Directors on February 2, 2021

REFERENCES

1. Carmi L, Tendler A, Bystritsky A, et al. Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. *Am J Psychiatry*. 11 2019;176(11):931-938. doi:10.1176/appi.ajp.2019.18101180
2. Pauls DL, Abramovitch A, Rauch SL, Geller DA. Obsessive-compulsive disorder: an integrative genetic and neurobiological perspective. *Nat Rev Neurosci*. Jun 2014;15(6):410-24. doi:10.1038/nrn3746
3. Menchón JM, van Ameringen M, Dell'Osso B, et al. Standards of care for obsessive-compulsive disorder centres. *Int J Psychiatry Clin Pract*. Sep 2016;20(3):204-8. doi:10.1080/13651501.2016.1197275
4. Ahmari SE, Dougherty DD. DISSECTING OCD CIRCUITS: FROM ANIMAL MODELS TO TARGETED TREATMENTS. *Depress Anxiety*. Aug 2015;32(8):550-62. doi:10.1002/da.22367
5. Boes AD, Kelly MS, Trapp NT, Stern AP, Press DZ, Pascual-Leone A. Noninvasive Brain Stimulation: Challenges and Opportunities for a New Clinical Specialty. *J Neuropsychiatry Clin Neurosci*. 2018;30(3):173-179. doi:10.1176/appi.neuropsych.17110262
6. Ooms P, Mantione M, Figeo M, Schuurman PR, van den Munckhof P, Denys D. Deep brain stimulation for obsessive-compulsive disorders: long-term analysis of quality of life. *J Neurol Neurosurg Psychiatry*. Feb 2014;85(2):153-8. doi:10.1136/jnnp-2012-302550
7. De Ridder D, Vanneste S, Gillett G, Manning P, Glue P, Langguth B. Psychosurgery Reduces Uncertainty and Increases Free Will? A Review. *Neuromodulation*. Apr 2016;19(3):239-48. doi:10.1111/ner.12405
8. Neumaier F, Paterno M, Alpdogan S, et al. Surgical Approaches in Psychiatry: A Survey of the World Literature on Psychosurgery. *World Neurosurg*. Jan 2017;97:603-634.e8. doi:10.1016/j.wneu.2016.10.008
9. Carmi L, Alyagon U, Barnea-Ygael N, Zohar J, Dar R, Zangen A. Clinical and electrophysiological outcomes of deep TMS over the medial prefrontal and anterior cingulate cortices in OCD patients. *Brain Stimul*. 2018 Jan - Feb 2018;11(1):158-165. doi:10.1016/j.brs.2017.09.004
10. Foa EB, McLean CP. The Efficacy of Exposure Therapy for Anxiety-Related Disorders and Its Underlying Mechanisms: The Case of OCD and PTSD. *Annu Rev Clin Psychol*. 2016;12:1-28. doi:10.1146/annurev-clinpsy-021815-093533
11. McGuire JF, Piacentini J, Lewin AB, Brennan EA, Murphy TK, Storch EA. A META-ANALYSIS OF COGNITIVE BEHAVIOR THERAPY AND MEDICATION FOR CHILD OBSESSIVE-COMPULSIVE DISORDER: MODERATORS OF TREATMENT EFFICACY, RESPONSE, AND REMISSION. *Depress Anxiety*. Aug 2015;32(8):580-93. doi:10.1002/da.22389
12. Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB, Association AP. Practice guideline for the treatment of patients with obsessive-compulsive disorder. *Am J Psychiatry*. Jul 2007;164(7 Suppl):5-53.
13. Flament MF, Bisserte JC. Pharmacologic treatment of obsessive-compulsive disorder: comparative studies. *J Clin Psychiatry*. 1997;58 Suppl 12:18-22.
14. Fineberg NA, Pampaloni I, Pallanti S, Ipser J, Stein DJ. Sustained response versus relapse: the pharmacotherapeutic goal for obsessive-compulsive disorder. *Int Clin Psychopharmacol*. Nov 2007;22(6):313-22. doi:10.1097/YIC.0b013e32825ea312
15. Fineberg NA, Reghunandanan S, Simpson HB, et al. Obsessive-compulsive disorder (OCD): Practical strategies for pharmacological and somatic treatment in adults. *Psychiatry Res*. May 2015;227(1):114-25. doi:10.1016/j.psychres.2014.12.003
16. Fineberg NA, Reghunandanan S, Brown A, Pampaloni I. Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond. *Aust N Z J Psychiatry*. Feb 2013;47(2):121-41. doi:10.1177/0004867412461958
17. Pittenger C, Bloch MH. Pharmacological treatment of obsessive-compulsive disorder. *Psychiatr Clin North Am*. Sep 2014;37(3):375-91. doi:10.1016/j.psc.2014.05.006

* Approved by the CTMSS Board of Directors on February 2, 2021

18. Veale D, Miles S, Smallcombe N, Ghezai H, Goldacre B, Hodson J. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis. *BMC Psychiatry*. Nov 2014;14:317. doi:10.1186/s12888-014-0317-5
19. Simpson HB, Foa EB, Liebowitz MR, et al. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. *JAMA Psychiatry*. Nov 2013;70(11):1190-9. doi:10.1001/jamapsychiatry.2013.1932
20. Rojas-Corrales MO, Gibert-Rahola J, Mico JA. Role of atypical opiates in OCD. Experimental approach through the study of 5-HT(2A/C) receptor-mediated behavior. *Psychopharmacology (Berl)*. Feb 2007;190(2):221-31. doi:10.1007/s00213tendler006-0619-5
21. Lerner AJ, Wassermann EM, Tamir DI. Seizures from transcranial magnetic stimulation 2012-2016: Results of a survey of active laboratories and clinics. *Clin Neurophysiol*. 08 2019;130(8):1409-1416. doi:10.1016/j.clinph.2019.03.016
22. Tendler A, Roth Y, Zangen A. Rate of inadvertently induced seizures with deep repetitive transcranial magnetic stimulation. *Brain Stimul*. 2018 Nov - Dec 2018;11(6):1410-1414. doi:10.1016/j.brs.2018.09.001
23. Pereira LS, Müller VT, da Mota Gomes M, Rotenberg A, Fregni F. Safety of repetitive transcranial magnetic stimulation in patients with epilepsy: A systematic review. *Epilepsy Behav*. Apr 2016;57(Pt A):167-176. doi:10.1016/j.yebeh.2016.01.015
24. MagVenture receives FDA clearance for OCD. *Press Release*. August 2020. MagVenture receives FDA clearance for OCD. Accessed October 15, 2020.
25. Roth et al. Real-world efficacy of deep TMS for obsessive-compulsive disorder: Post marketing data collected from 22 clinical sites. *J Psychiatr Res*. Nov. 2020 doi:org/10.1016/j.jpsychires.2020.11.009
26. Roth et al. Deep transcranial magnetic stimulation for obsessive-compulsive disorder is efficacious even in patients who failed multiple medications and CBT. *Psychiatry research*. 2020 Aug; 290 113179 DOI: [10.1016/j.psychres.2020.113179](https://doi.org/10.1016/j.psychres.2020.113179)
27. Alyagon et al. Modifications of cognitive performance in the stroop task following deep rTMS treatment course in OCD patients. *Brain Stimulat*. 2020 Nov 10; 14(1) 48-50 DOI: [10.1016/j.brs.2020.11.008](https://doi.org/10.1016/j.brs.2020.11.008), PMID: [33186777](https://pubmed.ncbi.nlm.nih.gov/33186777/)
28. Harmelech et al. Do comorbid OCD-MDD patients need two separate dTMS protocols? *Brain Stimulat*. 2020 Mar 31; 13(4) 1000 1001 DOI: [10.1016/j.brs.2020.03.014](https://doi.org/10.1016/j.brs.2020.03.014), PMID: [32380442](https://pubmed.ncbi.nlm.nih.gov/32380442/)

* Approved by the CTMSS Board of Directors on February 2, 2021